

Comment on Kumar et al, page 369

# Evans syndrome: pathology and genomic hubris

V. Koneti Rao | National Institutes of Health

**In this issue of *Blood*, Kumar et al<sup>1</sup> describe a cohort of 24 children with Evans syndrome (pES) harboring a distinct signature of immune dysregulation: increased circulating follicular T-helper (cTfh) cells associated with chronic T-cell activation/exhaustion and decreased naïve CD4<sup>+</sup> T cells and class switched memory B (CSMB) cells.**


The seminal publication in 1951 by Robert Evans and colleagues titled “Primary thrombocytopenic purpura and acquired hemolytic anemia: evidence for a common etiology” led to the disorder being referred to as Evans syndrome (ES).<sup>2</sup> Many astute and farsighted observations were made in 1940s and 1950s by Evans and others on the etiopathogenesis of immune-mediated peripheral destruction of red cells and platelets even before the structure of DNA and proteins like immunoglobulins were described.<sup>3,4</sup>

The first sentence of 1 publication about “acquired” hemolytic anemia read “It is now evident that the syndrome of acquired hemolytic anemia represents a distinct entity which is separate in pathogenesis and course from the commonly described familial hemolytic jaundice,” noted as distinct from what were then known as inherited red blood cell disorders such as thalassemia and sickle cell disease.<sup>5</sup> Coombs et al<sup>6</sup> described

agglutination of red blood cells weakly sensitized to human Rh blood group antibodies observable under a microscope in the hemolytic disease of the newborn in 1945. In 1947, Evans and colleagues demonstrated antibodies (they called it a “fraction of the plasma protein, probably a globulin”) against red blood cells in “acquired” hemolytic anemia with anti-human globulin containing rabbit serum.<sup>7</sup> However, Evans et al<sup>7</sup> also lamented “Since there is no technic comparable to the reticulocyte count for estimating the rate of formation of thrombocytes or to the determination of the pyrrhrole pigment excretion for measuring the rate of their destruction, it has not been possible to measure the rate of thrombocyte destruction or formation.” Alas, to this day, elucidating peripheral platelet destruction remains equally daunting for any student of hematology because there is no reticulocyte count or Coomb’s direct antiglobulin test for platelets analogous to the clinical tests readily available for the study of red cell fate in

anemia. The paper dating back to 1951 from Evans et al reports their 29 patients with primary thrombocytopenic purpura and acquired hemolytic anemia divided into 5 groups with cross-relationships in a chart to surmise common etiology and familial inheritance patterns (see figure). In addition to the occurrence of 2 diseases in the same person, spontaneous remissions and exacerbations were also noted in many. The authors posited that the spleen is a site of antibody production, although not the sole organ at fault. Their cohort also included 1 instance of a father and daughter presenting with primary thrombocytopenic purpura, which led them to observe “the tendency to produce anti-thrombocyte antibody was inherited.”<sup>2</sup> Incidentally the terms immune hemolytic anemia and immune thrombocytopenia currently in vogue were first coined by Evans, who eschewed use of the term “idiopathic” thrombocytopenic purpura as far back as in 1951. Known to his colleagues and friends as Bud Evans, he was a native Seattleite. Unfortunately, Evans was killed in a tragic car accident on Mercer Island in 1974 at the young age of 62.

Today we have reached full circle identifying many inherited monogenic causes of what Evans believed to be “acquired” immune hemolytic anemia and immune thrombocytopenia.<sup>8</sup> However, despite relatively easy and affordable access to panel-based next-generation genetic testing in 2021, we do not have a good genetic explanation in 50% to 60% of patients with ES to implicate their underlying pathology and use it for targeted treatments.<sup>9,10</sup> In the cohort reported



This figure was modified from Evans et al<sup>2</sup> and shows their cohort of 29 patients with ITP and AIHA in 5 groups with spectrum-like cross-relationships in a chart to surmise common etiology and 1 example of familial inheritance pattern. Photograph of Robert Evans—credit: University of Washington School of Medicine (<https://medicine.uw.edu/people/about-dr-evans>).

here by Kumar et al, only 12 of 24 patients had a pathogenic or likely pathogenic genetic variant. Hence, they propose a 4-point scoring system of biomarkers based on cTfh frequency, CD4 effector memory cell activation, frequency of naïve CD4<sup>+</sup> T cells, and B-cell maturation defects seen as decreased CSMB cells noted in all 24 patients with pES, irrespective of their genetic etiology. However, this degree of obedient clustering of distinct immune profiles in patients with ES need to be reproducible in the hands of other investigators in larger cohorts. Most patients in their cohort of 24 had some degree of lymphoproliferation and pulmonary or gastrointestinal manifestations. These associations underscore the importance of looking for similar clinical clues in all patients presenting with suspected ES. These observations might help us better understand the pathobiology of pES and provide some rational and empirical basis for therapies guided by cellular phenotyping through immune profile-based scoring system, especially in the remainder of the patients with pES where no known genetic cause can yet be discerned. Today the eponymous syndrome named after Evans remains an omnibus placeholder clinical diagnosis just like another immune disorder known as common variable immune deficiency, where the main function is to help insurance providers code the patients for reimbursements. Complete and further diagnostic work-up of both adult and pediatric patients with ES can provide clues for treatments. This goal can be accomplished by multicenter collaborative clinical trials performing upfront genetic testing and cellular immunophenotyping of every patient presenting with multilineage autoimmune cytopenias as has been proposed by Kumar et al.

*Conflict-of-interest disclosure:* The author declares no competing financial interests. ■

## REFERENCES

1. Kumar D, Prince C, Bennett CM, et al. T-follicular helper cell expansion and chronic T-cell activation are characteristic immune anomalies in Evans syndrome. *Blood*. 2022; 139(3):369-383.
2. Evans RS, Takahashi K, Duane RT, Payne R, Liu C. Primary thrombocytopenic purpura and acquired hemolytic anemia; evidence for a common etiology. *AMA Arch Intern Med*. 1951;87(1): 48-65.
3. Watson JD, Crick FH. Molecular structure of nucleic acids: a structure for deoxyribose nucleic acid. *Nature*. 1974;248(5451):765.
4. Black CA. A brief history of the discovery of the immunoglobulins and the origin of the modern immunoglobulin nomenclature. *Immunol Cell Biol*. 1997;75(1):65-68.
5. Evans RS, Duane RT. Acquired hemolytic anemia; the relation of erythrocyte antibody production to activity of the disease; the significance of thrombocytopenia and leukopenia. *Blood*. 1949;4(11):1196-1213.
6. Coombs RRA, Mourant AE, Race RR. Detection of weak and "incomplete" Rh agglutinins: a new test. *Lancet*. 1945; 246(6358):15-16.
7. Evans RS, Duane RT, Behrendt V. Demonstration of antibodies in acquired hemolytic anemia with anti-human globulin serum. *Proc Soc Exp Biol Med*. 1947; 64(3):372-375.
8. Hadjadj J, Aladjidi N, Fernandes H, et al; members of the French Reference Center for Pediatric Autoimmune Cytopenia (CEREVANCE). Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes. *Blood*. 2019;134(1):9-21.
9. Seif AE, Manno CS, Sheen C, Grupp SA, Teachey DT. Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study. *Blood*. 2010;115(11): 2142-2145.
10. Notarangelo LD, Uzel G, Rao VK. Primary immunodeficiencies: novel genes and unusual presentations. *Hematology (Am Soc Hematol Educ Program)*. 2019; 2019(1):443-448.

DOI 10.1182/blood.2021013636

© 2022 by The American Society of Hematology

## LYMPHOID NEOPLASIA

Comment on Fishman et al, page 399

# T/myeloid MPAL: origin and pathogenesis

Matthew P. McCormack | Monash University

**In this issue of *Blood*, Fishman et al have for the first time developed a pre-clinical model of T/myeloid mixed phenotype acute leukemia (MPAL) that faithfully recapitulates the human disease by using a fusion oncoprotein that they had previously identified in this leukemia subtype.<sup>1</sup> This work provides important insights into the cellular origin and molecular pathogenesis of this disease and provides, for the first time, a preclinical model that can be used to test new therapeutics.**

MPAL is a rare leukemia subtype with poor prognosis that is characterized by immunophenotypic features of both myeloid and lymphoid lineages. The majority of patients with MPAL have features of either B-cell and myeloid lineages or T-cell and myeloid lineages (T/myeloid MPAL).<sup>2</sup> MPAL is particularly difficult to treat, in part because it is unclear whether MPAL should be treated as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or a combination of both.<sup>3</sup> The cell of origin and molecular basis of this disease, in particular the causes of its biphenotypic nature, are unclear. This in turn makes optimal clinical care equally unclear.

Recent sequencing studies have defined the molecular landscape of T/myeloid MPAL and identified alterations in transcriptional regulators as a defining

feature of this disease, including recurrent mutually exclusive alterations or deletions in *WT1*, *ETV6*, *RUNX1*, and *CEBPA*, which are complemented by mutations in epigenetic regulators and activating mutations in signaling pathways.<sup>4,5</sup> This has also revealed that this disease is distinct from T-cell ALL (T-ALL) and AML but shares significant molecular and genomic similarity to early T-cell precursor-like ALL (ETP-ALL), another subtype of immature leukemia with poor prognosis.<sup>4,6</sup>

The ETS variant 6 (*ETV6*) gene is a member of the ETS family of transcription factors that encodes a transcriptional repressor. In addition to *ETV6* loss-of-function mutations in T/myeloid MPAL, several *ETV6* fusion oncogenes have been identified.<sup>4,7</sup> One of these, *ETV6-NCOA2*, which fuses *ETV6* with the